Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:VIVOBIOT

VIVO BIO TECH LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹14.40
at close · 8 Oct 2026
▼ 1.09 (-7.04%)
ThemesBiotechnology· coreArtificial Intelligence· mention

Latest filings

  1. Vivo Bio Tech files Q2 FY27 dematerialization compliance certificate · Compliance
  2. All 4 resolutions passed at 39th AGM with 99.68% approval · Board & Shareholder Meetings
  3. Vivo Bio Tech 39th AGM outcome: 4 items passed, directors re-appointed · Board & Shareholder Meetings
All filings ↓
Ask Nexa about VIVO BIO TECH LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹53 Cr over the trailing twelve months.

Market Cap
₹32 Cr
P / E (TTM)
3.4×
EV / EBITDA
4.6×
Div Yield
—
Growth
0.6%▲
Revenue 5y CAGR
PAT — · EBITDA +3.7%
Quality
11.9%·
ROCE (5y median)
ROE 4.8% (5y median) · margin 39.9%
Leverage
0.72·
Debt / Equity · moderate
Net debt ₹66 Cr
Revenue FY21→FY26
1.0×▲
Margin −14.2 pts
₹52 Cr → ₹53 Cr
Cash conversion
6.54×▲
Operating cash ÷ profit · 5 yrs
₹85 Cr on ₹13 Cr
Where it sits among 191 Pharmaceuticals & Biotechnology peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#3/164
P/B#5/169
ROCE#142/189
ROE#152/172
Debt / Equity#153/172
EBITDA margin#32/170
Revenue growth#83/166
Profit growth#163/164

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals & Biotechnology peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹13 Cr of profit and ₹85 Cr of operating cash — 6.54×
Profit is converting into cash
Concerns
Slow revenue growth — 1% a year over 5 years
Erratic profits — up in only 2 of the last 5 years
Carries more debt than its peers — 0.72× equity
higher than 89% of its 172 Pharmaceuticals & Biotechnology peers
Heavy working capital — 123 days of cash tied up
Customers are taking longer to pay — 51 → 80 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

VIVOBIOT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from VIVO BIO TECH LTD.'s filed financials and exchange disclosures

What does VIVO BIO TECH LTD. do?

VIVO BIO TECH LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol VIVOBIOT.

Is VIVO BIO TECH LTD. profitable?

No. Over the trailing twelve months VIVO BIO TECH LTD. reported a net loss of ₹1.71 Cr on revenue of ₹53 Cr.

Does VIVO BIO TECH LTD. pay a dividend?

Not in the latest reported year — VIVO BIO TECH LTD.'s dividend payout for FY26 was nil.

Is VIVO BIO TECH LTD. debt-free?

No. It reported borrowings of ₹67 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹66 Cr after cash. Debt stands at 0.72× equity. That is higher than 89% of its 172 Pharmaceuticals & Biotechnology peers.

Is VIVO BIO TECH LTD. expensive compared with its peers?

On trailing P/E, VIVO BIO TECH LTD. ranks 3 of 164 in Pharmaceuticals & Biotechnology — cheaper than 99% of them, against an industry median of 31.6×. This is a position, not a valuation judgement.

Where can I track VIVO BIO TECH LTD.'s announcements?

Every NSE and BSE filing by VIVO BIO TECH LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.